Scantox offers a comprehensive portfolio of drug discovery, development and CMC/Analytical services to support pharmaceutical, biotech and medical device industries.
Scantox Neuro was formerly QPS Neuropharmacology. We are specialists in Neuropharmacology and offer preclinical studies in CNS diseases, Rare Diseases and Mental Disorders but also within Oncology, Infectious diseases along with PK/PD studies in a variety of species. The on-site availability of highly predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes makes Scantox the first choice for most CNS drug development needs. Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease (NPC1), Gaucher Disease, Autism Spectrum Disorder (ASD), Schizophrenia, Frontotemporal Lobar Degeneration (FTLD) and other neurodegenerative and rare diseases.
Other discovery areas offered include exploratory toxicology, pharmacokinetics and pharmacodynamics, efficacy models for various indications, wound healing, safety pharmacology and local tolerance studies and a variety of species, including rodents, rabbits and minipigs.
Why Scantox
- Customer satisfaction is our absolute priority
- Your timeline is our timeline
- Every study is custom-built
- Scientific input to study design and data interpretation
- Extensive experience with virtually all drug targets and treatment types
- Wide range of validated models and techniques for comprehensive compound tests from a single source
- Highest degree of animal welfare and quality standards
